EHA 2021 | REFINE: updated data on navitoclax and ruxolitinib for myelofibrosis
Naveen Pemmaraju, MD, MD Anderson Cancer Center, Houston, TX, discusses the findings of the Phase II REFINE trial (NCT03222609) of navitoclax and ruxolitinib for patients with myelofibrosis. Navitoclax is an oral small-molecule inhibitor of antiapoptotic B-cell lymphoma 2 proteins, and ruxolitinib is a Janus kinase 1/2 inhibitor. Dr Pemmaraju reports that analysis of follow-up data from 34 patients who received ruxolitinib and navitoclax demonstrates promising results with a manageable toxicity profile. At a median follow-up of 105 weeks, the median overall survival was not reached. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
Disclosures
Naveen Pemmaraju, MD, is a member of the ASH Communications Committee and the ASCO Leukemia Advisory panel; has participated in consultancy work for Pacylex Pharmaceuticals, ImmuniGen, Bristol Myers Squibb, Blueprint Medicines, Clearview Healthcare Partners, Astellas Pharma US Inc., Triptych Health Partners and CTI Biopharma; has received grants from Affymetrix and SagerStrong Foundation; has received honoraria from Incyte, Novartis, LFB Biotechnologies, Stemline Therapeutics, Celgene, AbbVie, MustangBio, Roche Diagnostics, Blueprint Medicines, DAVA Oncology, Springer Science + Business Media LLC, Aptitude Health, NeoPharm Israel and CareDx, Inc., has received research support from Novartis, Stemline Therapeutics, Samus Therapeutics, AbbVie, Cellectis, Affymetrix, Daiichi Sankyo and Plexxikon; and has received travel reimbursement from Stemline Therapeutics, Celgene, MustangBio, DAVA Oncology and AbbVie.
